IONIS PHARMACEUTICALS ($IONS) posted quarterly earnings results on Wednesday, July 30th. The company reported earnings of $0.86 per share, beating estimates of -$0.52 by $1.38. The company also reported revenue of $452,000,000, beating estimates of $291,257,674 by $160,742,326.
You can see Quiver Quantitative's $IONS stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
IONIS PHARMACEUTICALS Insider Trading Activity
IONIS PHARMACEUTICALS insiders have traded $IONS stock on the open market 16 times in the past 6 months. Of those trades, 1 have been purchases and 15 have been sales.
Here’s a breakdown of recent trading of $IONS stock by insiders over the last 6 months:
- BRETT P MONIA (Chief Executive Officer) has made 0 purchases and 4 sales selling 53,385 shares for an estimated $1,712,058.
- MICHAEL R HAYDEN purchased 15,000 shares for an estimated $477,900
- PATRICK R. O'NEIL (EVP CLO & General Counsel) has made 0 purchases and 3 sales selling 8,778 shares for an estimated $279,670.
- JOSEPH BAROLDI (EVP, Chief Business Officer) sold 3,928 shares for an estimated $111,555
- KYLE JENNE (EVP, Chf GL Pdt Str Ofcr) sold 3,016 shares for an estimated $85,533
- ELIZABETH L HOUGEN (EVP, Finance & CFO) sold 1,523 shares for an estimated $49,403
- EUGENE SCHNEIDER (EVP, Chf Clinical Develop Ofcr) sold 1,484 shares for an estimated $47,779
- RICHARD S GEARY (EVP, Chief Development Officer) sold 1,406 shares for an estimated $45,561
- ERIC SWAYZE (EVP Research) sold 1,367 shares for an estimated $44,162
- C FRANK BENNETT (EVP, Chief Scientific Officer) sold 1,327 shares for an estimated $43,079
- BRIAN BIRCHLER (EVP, Corp and Development Ops) sold 680 shares for an estimated $19,291
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
IONIS PHARMACEUTICALS Hedge Fund Activity
We have seen 155 institutional investors add shares of IONIS PHARMACEUTICALS stock to their portfolio, and 185 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- DEEP TRACK CAPITAL, LP added 2,630,279 shares (+136.0%) to their portfolio in Q1 2025, for an estimated $79,355,517
- T. ROWE PRICE INVESTMENT MANAGEMENT, INC. added 2,006,334 shares (+14.2%) to their portfolio in Q1 2025, for an estimated $60,531,096
- BVF INC/IL added 1,913,385 shares (+inf%) to their portfolio in Q1 2025, for an estimated $57,726,825
- CLEARBRIDGE INVESTMENTS, LLC removed 1,618,220 shares (-100.0%) from their portfolio in Q1 2025, for an estimated $48,821,697
- CITADEL ADVISORS LLC added 1,314,146 shares (+60.7%) to their portfolio in Q1 2025, for an estimated $39,647,784
- FMR LLC added 924,094 shares (+4.1%) to their portfolio in Q1 2025, for an estimated $27,879,915
- CAPITAL WORLD INVESTORS added 896,581 shares (+7.8%) to their portfolio in Q1 2025, for an estimated $27,049,848
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
IONIS PHARMACEUTICALS Analyst Ratings
Wall Street analysts have issued reports on $IONS in the last several months. We have seen 6 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Barclays issued a "Overweight" rating on 07/01/2025
- HC Wainwright & Co. issued a "Buy" rating on 06/26/2025
- Guggenheim issued a "Buy" rating on 05/01/2025
- Needham issued a "Buy" rating on 04/30/2025
- Citigroup issued a "Buy" rating on 02/20/2025
- RBC Capital issued a "Outperform" rating on 02/20/2025
To track analyst ratings and price targets for IONIS PHARMACEUTICALS, check out Quiver Quantitative's $IONS forecast page.
IONIS PHARMACEUTICALS Price Targets
Multiple analysts have issued price targets for $IONS recently. We have seen 9 analysts offer price targets for $IONS in the last 6 months, with a median target of $55.0.
Here are some recent targets:
- Gena Wang from Barclays set a target price of $57.0 on 07/01/2025
- Mitchell Kapoor from HC Wainwright & Co. set a target price of $50.0 on 06/26/2025
- Jessica Fye from JP Morgan set a target price of $48.0 on 06/12/2025
- Debjit Chattopadhyay from Guggenheim set a target price of $64.0 on 05/01/2025
- Joseph Stringer from Needham set a target price of $55.0 on 04/30/2025
- Joshua Smith from Redburn Atlantic set a target price of $39.0 on 03/31/2025
- David Lebowitz from Citigroup set a target price of $64.0 on 02/20/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
